Nkarta (NKTX) News Today $7.04 +0.13 (+1.88%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 25 at 6:36 AM | americanbankingnews.comNkarta (NASDAQ:NKTX) Receives "Buy" Rating from HC WainwrightJuly 24 at 3:32 PM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Nkarta (NASDAQ:NKTX)HC Wainwright reiterated a "buy" rating and issued a $23.00 target price on shares of Nkarta in a report on Wednesday.July 24 at 3:04 PM | markets.businessinsider.comBuy Rating Confirmed: Expanding Potential of Nkarta’s NKX019 in SLE TreatmentJuly 24 at 10:03 AM | sg.finance.yahoo.comBRIEF-Ley Choon Group Says Units Secured Contracts Worth S$14 MlnJuly 24 at 6:00 AM | globenewswire.comNkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus ErythematosusJuly 20, 2024 | americanbankingnews.comAlicia J. Hager Sells 3,396 Shares of Nkarta, Inc. (NASDAQ:NKTX) StockJuly 19, 2024 | insidertrades.comNkarta, Inc. (NASDAQ:NKTX) Insider Alicia J. Hager Sells 3,396 SharesJuly 16, 2024 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Sees Significant Growth in Short InterestNkarta, Inc. (NASDAQ:NKTX - Get Free Report) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 7,360,000 shares, an increase of 22.9% from the June 15th total of 5,990,000 shares. Based on an average daily volume of 812,900 shares, the short-interest ratio is presently 9.1 days.July 16, 2024 | globenewswire.comNkarta Announces Leadership Updates, Appoints Nadir Mahmood as PresidentJuly 15, 2024 | marketbeat.comSusquehanna Fundamental Investments LLC Makes New $788,000 Investment in Nkarta, Inc. (NASDAQ:NKTX)Susquehanna Fundamental Investments LLC purchased a new position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 72,898 shares of the company's stock, valued at aJuly 3, 2024 | marketbeat.comWasatch Advisors LP Has $12.63 Million Stake in Nkarta, Inc. (NASDAQ:NKTX)Wasatch Advisors LP lessened its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 44.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,168,492 shares of the company's stock after selling 931,207 shares during the pJuly 1, 2024 | investorplace.com3 Undervalued Stocks Primed for a 2X ReturnJune 27, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $23.00 price target on shares of Nkarta in a report on Thursday.June 27, 2024 | globenewswire.comNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsJune 14, 2024 | marketbeat.comBoxer Capital LLC Acquires Shares of 1,440,000 Nkarta, Inc. (NASDAQ:NKTX)Boxer Capital LLC acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,440,000 shares of the company's stock, valued at approximJune 13, 2024 | globenewswire.comNkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsJune 12, 2024 | marketbeat.comCommodore Capital LP Invests $18.02 Million in Nkarta, Inc. (NASDAQ:NKTX)Commodore Capital LP acquired a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,730,000 shares of the company's stock, valued at apprJune 11, 2024 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Shares Bought by Wasatch Advisors LPWasatch Advisors LP increased its stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 13.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,099,699 shares of the company's stock after buying an additional 251,795 shareJune 10, 2024 | marketbeat.comSuperstring Capital Management LP Buys Shares of 347,381 Nkarta, Inc. (NASDAQ:NKTX)Superstring Capital Management LP bought a new stake in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 347,381 shares of the company's stock, valued at approximately $2,293,000. Nkarta accounts foJune 3, 2024 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Short Interest UpdateNkarta, Inc. (NASDAQ:NKTX - Get Free Report) saw a large increase in short interest in May. As of May 15th, there was short interest totalling 8,040,000 shares, an increase of 16.0% from the April 30th total of 6,930,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is currently 8.0 days.May 18, 2024 | morningstar.comNkarta Inc Ordinary SharesMay 13, 2024 | marketbeat.comNeedham & Company LLC Cuts Nkarta (NASDAQ:NKTX) Price Target to $13.00Needham & Company LLC dropped their price objective on shares of Nkarta from $15.00 to $13.00 and set a "buy" rating for the company in a report on Monday.May 13, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Price Target Increased to $23.00 by Analysts at HC WainwrightHC Wainwright raised their price objective on shares of Nkarta from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Monday.May 10, 2024 | finance.yahoo.comNkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational AnalysisMay 10, 2024 | finanznachrichten.deNkarta, Inc.: Nkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 10, 2024 | markets.businessinsider.comNkarta Inc. Buy Rating Affirmed Amidst Promising Clinical Studies and Robust Financial HealthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Nkarta’s NKX019 Shows Promise in Lupus Nephritis Clinical TrialsMay 10, 2024 | investorplace.comNKTX Stock Earnings: Nkarta Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 9, 2024 | globenewswire.comNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 7, 2024 | investorplace.comOpportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's RadarApril 27, 2024 | msn.comAmgen’s Blincyto data send Cullinan higherApril 27, 2024 | seekingalpha.comNkarta: Down 50% Since March With A Clinical Catalyst AheadApril 18, 2024 | finance.yahoo.comNkarta, Inc. (NKTX) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)April 10, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)April 10, 2024 | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Nkarta (NASDAQ:NKTX)Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Nkarta in a report on Wednesday.April 8, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 5, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of InvestorsApril 3, 2024 | globenewswire.comNkarta to Participate in Upcoming Investor ConferencesApril 2, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Stock Price Down 5.7%Nkarta (NASDAQ:NKTX) Stock Price Down 5.7%April 1, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Shares Gap Up to $10.81Nkarta (NASDAQ:NKTX) Shares Gap Up to $10.81March 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 30, 2024 | insidertrades.comSimeon George Purchases 2,000,000 Shares of Nkarta, Inc. (NASDAQ:NKTX) StockMarch 28, 2024 | marketbeat.comNkarta, Inc. (NASDAQ:NKTX) Director Acquires $20,000,000.00 in StockNkarta, Inc. (NASDAQ:NKTX - Get Free Report) Director Simeon George bought 2,000,000 shares of the business's stock in a transaction on Wednesday, March 27th. The shares were purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the purchase, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.March 27, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)March 27, 2024 | msn.comPromising Biopharma Nkarta (NASDAQ:NKTX) Not For the Faint-HeartedMarch 26, 2024 | marketbeat.comNkarta (NASDAQ:NKTX) Price Target Increased to $16.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group increased their price target on shares of Nkarta from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday.March 26, 2024 | sg.finance.yahoo.comNkarta, Inc. (NKTX) interactive stock chart – Yahoo Finance Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Man Who Called Nvidia at $1.10 Says Buy This Now... (Ad)In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. Watch Alex's "Next Magnificent Seven" presentation now. NKTX Media Mentions By Week NKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTX News Sentiment▼0.680.62▲Average Medical News Sentiment NKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTX Articles This Week▼82▲NKTX Articles Average Week Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fate Therapeutics News Today Phathom Pharmaceuticals News Today Longboard Pharmaceuticals News Today Belite Bio News Today Arcus Biosciences News Today Ardelyx News Today Dynavax Technologies News Today Indivior News Today Day One Biopharmaceuticals News Today ANI Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.